Q1 Earnings Estimate for Metagenomi Issued By HC Wainwright

Metagenomi, Inc. (NASDAQ:MGX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Metagenomi in a research note issued on Tuesday, May 27th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($0.66) for the quarter. HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Metagenomi's current full-year earnings is ($2.46) per share. HC Wainwright also issued estimates for Metagenomi's Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.75) EPS and Q4 2026 earnings at ($0.79) EPS.

Other equities analysts also recently issued reports about the company. Wells Fargo & Company restated an "overweight" rating and set a $16.00 price target (down from $20.00) on shares of Metagenomi in a report on Wednesday, May 14th. Wall Street Zen downgraded shares of Metagenomi from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Finally, Chardan Capital reduced their price objective on shares of Metagenomi from $13.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $13.00.

Metagenomi Stock Performance

Shares of Metagenomi stock traded down $0.09 during midday trading on Wednesday, hitting $1.69. The company had a trading volume of 260,689 shares, compared to its average volume of 793,826. Metagenomi has a 52-week low of $1.23 and a 52-week high of $6.90. The stock has a market capitalization of $63.19 million, a P/E ratio of -0.80 and a beta of -0.65. The company has a 50 day moving average of $1.56 and a 200 day moving average of $2.24.

Metagenomi (NASDAQ:MGX - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.06). Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%. The business had revenue of $4.13 million for the quarter, compared to the consensus estimate of $8.75 million.

Institutional Investors Weigh In On Metagenomi

Hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC purchased a new position in shares of Metagenomi in the first quarter worth approximately $119,000. Nuveen LLC bought a new position in Metagenomi in the first quarter worth approximately $86,000. Virtu Financial LLC purchased a new position in shares of Metagenomi during the 1st quarter worth $43,000. Bank of New York Mellon Corp grew its position in shares of Metagenomi by 39.6% during the 1st quarter. Bank of New York Mellon Corp now owns 50,387 shares of the company's stock valued at $69,000 after acquiring an additional 14,296 shares during the period. Finally, Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Metagenomi during the 4th quarter valued at $92,000.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.